Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Share-based Compensation: 2010-2024

Historic Share-based Compensation for Iovance Biotherapeutics (IOVA) over the last 14 years, with Dec 2024 value amounting to $109.6 million.

  • Iovance Biotherapeutics' Share-based Compensation fell 61.62% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year decrease of 13.23%. This contributed to the annual value of $109.6 million for FY2024, which is 75.05% up from last year.
  • As of FY2024, Iovance Biotherapeutics' Share-based Compensation stood at $109.6 million, which was up 75.05% from $62.6 million recorded in FY2023.
  • Over the past 5 years, Iovance Biotherapeutics' Share-based Compensation peaked at $109.6 million during FY2024, and registered a low of $40.9 million during FY2020.
  • Over the past 3 years, Iovance Biotherapeutics' median Share-based Compensation value was $84.0 million (recorded in 2022), while the average stood at $85.4 million.
  • In the last 5 years, Iovance Biotherapeutics' Share-based Compensation declined by 25.47% in 2023 and then spiked by 75.05% in 2024.
  • Iovance Biotherapeutics' Share-based Compensation (Yearly) stood at $40.9 million in 2020, then surged by 70.63% to $69.8 million in 2021, then increased by 20.44% to $84.0 million in 2022, then dropped by 25.47% to $62.6 million in 2023, then spiked by 75.05% to $109.6 million in 2024.